Title |
Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
|
---|---|
Published in |
Malaria Journal, March 2016
|
DOI | 10.1186/s12936-016-1240-7 |
Pubmed ID | |
Authors |
Kyaw Myo Tun, Atthanee Jeeyapant, Mallika Imwong, Min Thein, Sai Soe Moe Aung, Tin Maung Hlaing, Prayoon Yuentrakul, Cholrawee Promnarate, Mehul Dhorda, Charles J. Woodrow, Arjen M. Dondorp, Elizabeth A. Ashley, Frank M. Smithuis, Nicholas J. White, Nicholas P. J. Day |
Abstract |
Artemisinin resistance in Plasmodium falciparum extends across Southeast Asia where it is associated with worsening partner drug resistance and a decline in the efficacy of frontline artemisinin-based combination therapy. Dihydroartemisinin-piperaquine (DP) is an essential component of preventive and curative treatment in the region, but its therapeutic efficacy has fallen in Cambodia. A prospective clinical and parasitological evaluation of DP was conducted at two sites in Upper Myanmar between August 2013 and December 2014, enrolling 116 patients with acute uncomplicated falciparum malaria. Patients received DP orally for 3 days together with primaquine 0.25 mg/kg on admission. Parasite clearance half-lives based on 6 hourly blood smears, and day 42 therapeutic responses were assessed as well as parasite K13 genotypes. Median parasite clearance half-life was prolonged, and clearance half-life was greater than 5 h in 21 % of patients. Delayed parasite clearance was significantly associated with mutations in the propeller region of the parasite k13 gene. The k13 F446I mutation was found in 25.4 % of infections and was associated with a median clearance half-life of 4.7 h compared with 2.7 h for infections without k13 mutations (p < 0.001). There were no failures after 42 days of follow-up, although 18 % of patients had persistent parasitaemia on day 3. The dominant k13 mutation observed in Upper Myanmar, F446I, appears to be associated with an intermediate rate of parasite clearance compared to other common mutations described elsewhere in the Greater Mekong Subregion. Discerning this phenotype requires relatively detailed clearance measurements, highlighting the importance of methodology in assessing artemisinin resistance. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 8% |
Kenya | 1 | 8% |
Japan | 1 | 8% |
United States | 1 | 8% |
Unknown | 8 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 75% |
Science communicators (journalists, bloggers, editors) | 2 | 17% |
Scientists | 1 | 8% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | 1% |
Unknown | 71 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 15 | 21% |
Student > Ph. D. Student | 13 | 18% |
Student > Master | 9 | 13% |
Student > Bachelor | 5 | 7% |
Lecturer | 5 | 7% |
Other | 13 | 18% |
Unknown | 12 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 21% |
Agricultural and Biological Sciences | 13 | 18% |
Biochemistry, Genetics and Molecular Biology | 7 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
Immunology and Microbiology | 3 | 4% |
Other | 13 | 18% |
Unknown | 17 | 24% |